Crinetics Pharmaceuticals, Inc. (CRNX)
CRNX Stock Price Chart
Explore Crinetics Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze CRNX price movements and trends.
CRNX Company Profile
Discover essential business fundamentals and corporate details for Crinetics Pharmaceuticals, Inc. (CRNX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
18 Jul 2018
Employees
437.00
Website
https://www.crinetics.comCEO
R. Scott Struthers
Description
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
CRNX Financial Timeline
Browse a chronological timeline of Crinetics Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is -$1.23, while revenue estimate is $14.84m.
Earnings released on 7 May 2026
EPS came in at -$1.23 falling short of the estimated -$1.22 by -0.82%, while revenue for the quarter reached $10.73m , beating expectations by +26.07%.
Earnings released on 26 Feb 2026
EPS came in at -$1.29 surpassing the estimated -$1.37 by +5.84%, while revenue for the quarter reached $6.16m , beating expectations by +37.22%.
Earnings released on 6 Nov 2025
EPS came in at -$1.38 falling short of the estimated -$1.27 by -8.66%, while revenue for the quarter reached $143.00k , missing expectations by -96.69%.
Earnings released on 7 Aug 2025
EPS came in at -$1.23 falling short of the estimated -$1.13 by -8.85%, while revenue for the quarter reached $1.03m , beating expectations by +161.68%.
Earnings released on 8 May 2025
EPS came in at -$1.04 falling short of the estimated -$0.99 by -5.05%, while revenue for the quarter reached $361.00k , beating expectations by +3.76%.
Earnings released on 27 Feb 2025
EPS came in at -$0.88 surpassing the estimated -$0.92 by +4.35%.
Earnings released on 12 Nov 2024
EPS came in at -$0.96 falling short of the estimated -$0.91 by -5.42%.
Earnings released on 8 Aug 2024
EPS came in at -$0.94 falling short of the estimated -$0.86 by -9.30%, while revenue for the quarter reached $399.00k , missing expectations by -21.76%.
Earnings released on 9 May 2024
EPS came in at -$0.93 falling short of the estimated -$0.84 by -10.71%, while revenue for the quarter reached $640.00k , beating expectations by +146.15%.
Earnings released on 28 Feb 2024
EPS came in at -$0.90 falling short of the estimated -$0.89 by -1.12%.
Earnings released on 7 Nov 2023
EPS came in at -$1.01 falling short of the estimated -$0.89 by -13.48%, while revenue for the quarter reached $346.00k , beating expectations by +82.11%.
Earnings released on 8 Aug 2023
EPS came in at -$0.94 falling short of the estimated -$0.85 by -10.59%, while revenue for the quarter reached $988.00k , beating expectations by +605.71%.
Earnings released on 4 May 2023
EPS came in at -$0.85 falling short of the estimated -$0.82 by -3.66%, while revenue for the quarter reached $2.68m , beating expectations by +325.24%.
Earnings released on 28 Feb 2023
EPS came in at -$0.84 falling short of the estimated -$0.82 by -2.44%, while revenue for the quarter reached $709.00k , beating expectations by +183.60%.
Earnings released on 14 Nov 2022
EPS came in at -$0.78 matching the estimated -$0.78, while revenue for the quarter reached $458.00k , beating expectations by +83.20%.
Earnings released on 12 Aug 2022
EPS came in at -$0.81 falling short of the estimated -$0.62 by -30.65%, while revenue for the quarter reached $439.00k , missing expectations by -26.83%.
Earnings released on 12 May 2022
EPS came in at -$0.73 falling short of the estimated -$0.56 by -30.36%, while revenue for the quarter reached $3.13m , missing expectations by -39.79%.
Earnings released on 30 Mar 2022
EPS came in at -$0.68 falling short of the estimated -$0.57 by -19.30%, while revenue for the quarter reached $1.08m .
Earnings released on 5 Nov 2021
EPS came in at -$0.73 falling short of the estimated -$0.70 by -4.29%.
Earnings released on 10 Aug 2021
EPS came in at -$0.70 falling short of the estimated -$0.60 by -16.67%.
CRNX Stock Performance
Access detailed CRNX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
